ที่ FPI Ref. FPI.024/2018 12 November 2018 Subject : Management Discussion & Analysis of Performance Results of Quarter 3/2018 To : Board of Directors and President of The Stock Exchange of Thailand

Microsoft Word - MD&A Q1_2020 (Eng ) May 8, 2020 Subject : Interim Management Discussion and Analysis of Q1/2020 Attention : President of The Stock Exchange of Thailand We attach herewith the

ที่ FPI Ref. FPI.007/2020 15 July 2020 Subject : Management Discussion & Analysis of Performance Results of Quarter 1 2020 To : Board of Directors and President of The Stock Exchange of Thailand

MD&A Q2_2020 (Eng ) July 31, 2020 Subject : Interim Management Discussion and Analysis of Q2/2020 Attention : President of The Stock Exchange of Thailand We attach herewith the financial statements

[COMPANY NAME] Ref.: EFORL IR037/2020 September 11, 2020 Subject: Management Discussion and Analysis Quarter 2 Ending 30 June 2020 To President The Stock Exchange of Thailand 1. Overview financial

Page 1 of 4 No. RJH – SET 7/2020 11 May 2020 Subject : Management’s Discussion and Analysis for the First Quarter of 2020 To : The President The Stock Exchange of Thailand Rajthanee Hospital Public

(Translation) UAC.CS/012/2020 May 14, 2020 Subject: Explanation of the operating results for the first quarter period ended March 31, 2020 To: President The Stock Exchange of Thailand Attachment

August 11, 2020 Subject: Management’s Discussion and Analysis for the second Quarter of 2020 To: The President The Stock Exchange of Thailand (SET) DOD Biotech Public Company Limited and its subsidiaries

both total transaction amount and the number of kiosks, covering all area nationwide. The Company’s key strategy focuses on managing the kiosk location and adding new services to the system including the

managing costs appropriately and being more careful with investment plans. The Company expected that this quarter has the deepest contraction in transaction value, and the situation will be better due to